<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7281404\results\search\country\results.xml">
  <result pre="infection that causes COVID-19, and it first appeared in Wuhan," exact="China" post="in December 2019 and spread rapidly all over the"/>
  <result pre="that have implemented massive screening for the whole population, like" exact="South Korea," post="the overall case fatality may be less than 1%,"/>
  <result pre="well as post-influenza complications (only in a few countries including" exact="Russia" post="and China), [37]. Overall, umifenovir has a broad variety"/>
  <result pre="in late phases [61]. According to the guidelines implemented in" exact="China" post="for COVID-19 infection, IFNÎ± is to be administered by"/>
  <result pre="C5b-9 or membrane attack complex (MAC) from subsequent formation. In" exact="the United States," post="eculizumab is approved for treating paroxysmal nocturnal hemoglobinuria and"/>
  <result pre="or membrane attack complex (MAC) from subsequent formation. In the" exact="United States," post="eculizumab is approved for treating paroxysmal nocturnal hemoglobinuria and"/>
  <result pre="Clinical Guidance for COVID-19 Pneumonia Diagnosis and Treatment published by" exact="China" post="National Health Commission on 4 March 2020 included tocilizumab"/>
  <result pre="dangerous lung inflammation in 21 patients with severe COVID-19 in" exact="China" post="[91]. However, Health Canada notified healthcare providers that severe"/>
  <result pre="21 patients with severe COVID-19 in China [91]. However, Health" exact="Canada" post="notified healthcare providers that severe cases of drug-induced liver"/>
  <result pre="with COVID-19, most notably in a recent single-arm study in" exact="China" post="with tocilizumab in critically ill COVID-19 patients [94]. Currently,"/>
  <result pre="of 500 milligrams twice daily for ten days [109]. In" exact="the United States," post="the FDA endorsed an emergency use authorization to permit"/>
  <result pre="500 milligrams twice daily for ten days [109]. In the" exact="United States," post="the FDA endorsed an emergency use authorization to permit"/>
  <result pre="been used for the treatment of chronic pancreatitis patients in" exact="Japan" post="[141]. Therefore, camostat mesylate could also be of benefit"/>
 </snippets>
</snippetsTree>
